VRTX

CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP is rated a Buy.

SeekingAlpha · 1d ago

They could both outperform the market over the medium term, but one appears to have a clear edge.

Yahoo · 1d ago

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals has a market

Benzinga · 2d ago

Next Phase of Geophysical Work Advances Priority Targets Following August Technical StudyVANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce plans to undertake a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoundland and Labrador. The survey has been selected as the Co

Yahoo · 3d ago

My clustering stock screener is giving us a much more interesting macro signal than simply energy stocks are strong. The portfolio is not simply long commodities. It's long capital intensity

SeekingAlpha · 3d ago

We'll know a little more about the company's prospects by the end of the year.

Yahoo · 3d ago

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo · 4d ago